Takeshi Nishijima1, Takuro Shimbo, Hirokazu Komatsu, Yohei Hamada, Hiroyuki Gatanaga, Shinichi Oka. 1. *AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; †Center for AIDS Research, Kumamoto University, Kumamoto, Japan; ‡Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan; and §Department of Community Care, Saku Central Hospital, Nagano, Japan.
Abstract
BACKGROUND: The epidemiology of hepatitis C virus (HCV) infection among HIV-infected men who have sex with men (MSM) who do not inject drugs in Asia remains unknown. METHOD: The incidence and risk factors for incident HCV infection among HIV-infected MSM at a large HIV clinic in Tokyo were elucidated. Poisson regression compared the incidence of HCV seroconversion at different observation periods. RESULTS: Of 753 HIV-1 infected MSM patients negative for HCV antibody (HCVAb) at baseline and available follow-up HCVAb test, 21 patients (2.8%) seroconverted to HCVAb positive over 2246 person-years (PY), for an incidence of 9.35 per 1000 PY. The incidence increased over time from 0 per 1000 PY in 2005-2006, 3.0 per 1000 PY in 2007-2008, 7.7 per 1000 PY in 2009-2010, to 24.9 per 1000 PY in 2011-2012 (P = 0.012). Of 21 incident cases, only 4 (19%) were injection drug users, and sensitivity analysis that excluded injection drug users yielded similar findings. Multivariate analysis identified illicit drug use to be an independent risk for HCV infection (hazard ratio = 3.006; 95% confidence interval: 1.092 to 8.275; P = 0.033). CONCLUSIONS: Incident HCV infection is increasing among HIV-1-infected MSM noninjection drug users at resource-rich setting in Asia. Illicit drug use is an independent risk factor for incident HCV infection in this population.
BACKGROUND: The epidemiology of hepatitis C virus (HCV) infection among HIV-infectedmen who have sex with men (MSM) who do not inject drugs in Asia remains unknown. METHOD: The incidence and risk factors for incident HCV infection among HIV-infected MSM at a large HIV clinic in Tokyo were elucidated. Poisson regression compared the incidence of HCV seroconversion at different observation periods. RESULTS: Of 753 HIV-1 infected MSMpatients negative for HCV antibody (HCVAb) at baseline and available follow-up HCVAb test, 21 patients (2.8%) seroconverted to HCVAb positive over 2246 person-years (PY), for an incidence of 9.35 per 1000 PY. The incidence increased over time from 0 per 1000 PY in 2005-2006, 3.0 per 1000 PY in 2007-2008, 7.7 per 1000 PY in 2009-2010, to 24.9 per 1000 PY in 2011-2012 (P = 0.012). Of 21 incident cases, only 4 (19%) were injection drug users, and sensitivity analysis that excluded injection drug users yielded similar findings. Multivariate analysis identified illicit drug use to be an independent risk for HCV infection (hazard ratio = 3.006; 95% confidence interval: 1.092 to 8.275; P = 0.033). CONCLUSIONS: Incident HCV infection is increasing among HIV-1-infected MSM noninjection drug users at resource-rich setting in Asia. Illicit drug use is an independent risk factor for incident HCV infection in this population.
Authors: José Antonio Mata-Marín; Armando Abraham de Pablos-Leal; Stefan Mauss; Carla Ileana Arroyo-Anduiza; Mara Soraya Rodríguez-Evaristo; Luis Antonio Uribe-Noguéz; María de Los Ángeles Berrospe-Silva; Juan Carlos Lara-Castañeda; Edgar Pérez-Barragán; Jesús Gaytán-Martínez Journal: PLoS One Date: 2022-07-15 Impact factor: 3.752
Authors: Ashly E Jordan; David C Perlman; Joshua Neurer; Daniel J Smith; Don C Des Jarlais; Holly Hagan Journal: Int J STD AIDS Date: 2016-07-10 Impact factor: 1.359
Authors: Yun-Chi Chen; Kjell J Wiberg; Yu-Hsiang Hsieh; Arun Bansal; Philipe Bolzan; Janelle A Guy; Erastus N Maina; Andrea L Cox; Chloe L Thio Journal: Open Forum Infect Dis Date: 2016-06-29 Impact factor: 3.835
Authors: Daniel Bradshaw; Jayna Raghwani; Brendan Jacka; Rachel Sacks-Davis; Francois Lamoury; Ian Down; Garrett Prestage; Tanya L Applegate; Margaret Hellard; Joe Sasadeusz; Gregory J Dore; Oliver G Pybus; Gail V Matthews; Mark Danta Journal: PLoS One Date: 2016-09-01 Impact factor: 3.240
Authors: Joost W Vanhommerig; Femke A E Lambers; Janke Schinkel; Ronald B Geskus; Joop E Arends; Thijs J W van de Laar; Fanny N Lauw; Kees Brinkman; Luuk Gras; Bart J A Rijnders; Jan T M van der Meer; Maria Prins; J T M van der Meer; R Molenkamp; M Mutschelknauss; H E Nobel; H W Reesink; J Schinkel; M van der Valk; G E L van den Berk; K Brinkman; D Kwa; N van der Meche; A Toonen; D Vos; M van Broekhuizen; F N Lauw; J W Mulder; J E Arends; A van Kessel; I de Kroon; A Boonstra; M E van der Ende; S Hullegie; B J A Rijnders; T J W van de Laar; L Gras; C Smit; F A E Lambers; M Prins; J W Vanhommerig; W van der Veldt Journal: Open Forum Infect Dis Date: 2015-08-06 Impact factor: 3.835